SAI Parenteral Announces IPO Details with Price Band of Rs 372 to Rs 392 per Share
Hyderabad-based pharmaceutical company SAI Parenteral Limited has officially disclosed the price band for its upcoming initial public offering (IPO). The IPO is set with a price range of Rs 372 to Rs 392 per equity share, as confirmed in the company's regulatory filings. Subscription for the IPO will commence on March 24 and conclude on March 27, providing investors a four-day window to participate. Prior to this, anchor investor bidding is scheduled for March 23, marking a key step in the offering process.
IPO Structure and Allocation Details
The IPO follows the book-building route and comprises two main components: a fresh issue of up to Rs 285 crore, with each share having a face value of Rs 5, and an offer for sale of up to 31,57,880 equity shares by investor selling shareholders. This structure is outlined in the red herring prospectus submitted to the Securities and Exchange Board of India (Sebi), the capital markets regulator. Under the allocation framework, qualified institutional buyers will be allocated not more than 50% of the issue, ensuring significant institutional participation. Retail investors are guaranteed not less than 35% of the shares, promoting broader public involvement, while non-institutional investors will receive not less than 15%.
Utilization of Proceeds and Strategic Growth Plans
SAI Parenteral intends to utilize the net proceeds from the IPO for several strategic purposes aimed at enhancing its market position. Key areas of investment include capacity expansion to meet growing demand, facility upgrades to improve operational efficiency, and the development of research and development infrastructure to foster innovation. Additionally, funds will be allocated towards the repayment of borrowings, which will help reduce debt and strengthen the company's financial health, as well as for working capital requirements and general corporate purposes. The company has been actively expanding its global contract development and manufacturing organization (CDMO) presence, supported by recent acquisitions such as Noumed Pharmaceuticals in Australia and New Zealand. This move aligns with its strategy to target growth across regulated and export markets, positioning SAI Parenteral for long-term success in the competitive pharmaceutical industry.
